Bruno Scheller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1023969/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. Heart, 2022, 108, 458-466.	1.2	28
2	Drug-Coated Balloons for Coronary De Novo Disease – What Should Optimal Lesion Preparation Look Like?. Cardiovascular Revascularization Medicine, 2022, 35, 96-97.	0.3	1
3	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011325.	1.4	15
4	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. Clinical Research in Cardiology, 2022, 111, 806-815.	1.5	8
5	Treatment of Coronary De Novo LesionsÂby a Sirolimus- or Paclitaxel-Coated Balloon. JACC: Cardiovascular Interventions, 2022, 15, 770-779.	1.1	27
6	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011569.	1.4	17
7	Causes of death after treatment of small coronary artery disease with paclitaxel-coated balloons. Clinical Research in Cardiology, 2021, 110, 307-311.	1.5	6
8	Myocardial infarction in a patient with single coronary artery - rare but real. Journal of Cardiology Cases, 2021, 23, 246-249.	0.2	1
9	Valvular heart disease in patients with chronic kidney disease. Herz, 2021, 46, 228-233.	0.4	10
10	Late lumen enlargement after treatment of de-novo lesions with drug coated balloon catheters – Glagov effect or plaque regression?. International Journal of Cardiology, 2021, 329, 79-81.	0.8	4
11	Efficacy and safety of a magnesium stearate paclitaxel coated balloon catheter in the porcine coronary model. International Journal of Cardiology, 2021, 331, 46-56.	0.8	4
12	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. Biomedicine and Pharmacotherapy, 2021, 138, 111469.	2.5	3
13	Preclinical Evaluation of the Temporary Drug-Coated Spur Stent System in Porcine Peripheral Arteries. Journal of Endovascular Therapy, 2021, 28, 938-949.	0.8	3
14	Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2021, 14, 1789-1798.	1.1	22
15	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. Atherosclerosis, 2021, 332, 48-54.	0.4	28
16	A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions. PLoS ONE, 2021, 16, e0259106.	1.1	3
17	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. Diabetes Epidemiology and Management, 2021, 4, 100022.	0.4	1
18	Novel, vessel anatomy adjusting drugâ€coated balloon—Preclinical evaluation in peripheral porcine arteries. Catheterization and Cardiovascular Interventions, 2020, 95, 319-328.	0.7	2

#	Article	IF	CITATIONS
19	Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis. European Heart Journal, 2020, 41, 3729-3731.	1.0	11
20	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clinical Research in Cardiology, 2020, 109, 845-856.	1.5	24
21	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet, The, 2020, 396, 1504-1510.	6.3	96
22	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. Clinical Research in Cardiology, 2020, 109, 1500-1506.	1.5	50
23	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. Journal of the American College of Cardiology, 2020, 76, 2321-2330.	1.2	154
24	Drug-Coated Balloons for CoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1391-1402.	1.1	218
25	Editorial: Rotational Atherectomy Followed by Drug-Coated Balloons in Calcified Coronary De Novo Lesions – An Alternative to Stent Implantation?. Cardiovascular Revascularization Medicine, 2020, 21, 654-656.	0.3	2
26	Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic. Clinical Research in Cardiology, 2020, 109, 1507-1509.	1.5	0
27	Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial. Clinical Research in Cardiology, 2020, 109, 1223-1231.	1.5	5
28	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	1.2	70
29	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a PatientÂWith HOCM. JACC: Case Reports, 2020, 2, 384-388.	0.3	2
30	Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. Clinical Research in Cardiology, 2020, 109, 1114-1124.	1.5	18
31	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovascular Diabetology, 2020, 19, 215.	2.7	30
32	Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention, 2020, 15, 1527-1533.	1.4	60
33	Clinical outcome after interventions with paclitaxel-coated balloons: a PCR statement. EuroIntervention, 2020, 15, 1225-1227.	1.4	3
34	Drug-coated balloon angioplasty for in-stent restenosis – a question of the right device or the right patient selection and technique?. EuroIntervention, 2020, 16, e276-e278.	1.4	1
35	Drug-coated balloons for patients with increased risk of bleeding. Lancet, The, 2019, 394, 190-192.	6.3	0
36	Treatment of in-Stent Restenosis - What is Important in the Interest of the Patient?. Cardiovascular Revascularization Medicine, 2019, 20, 544-545.	0.3	0

#	Article	IF	CITATIONS
37	Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. JACC: Cardiovascular Interventions, 2019, 12, 558-566.	1.1	82
38	Coronary artery treatment with a urea-based paclitaxel-coated balloon: the European-wide FALCON all-comers DCB Registry (FALCON Registry). EuroIntervention, 2019, 15, e382-e388.	1.4	16
39	Drugâ€coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKETâ€SMALL 2. Clinical Cardiology, 2018, 41, 569-575.	0.7	13
40	Plasma levels of the oxyphytosterol 7α-hydroxycampesterol are associated with cardiovascular events. Atherosclerosis, 2018, 279, 17-22.	0.4	20
41	Drug Distribution and Basic Pharmacology of Paclitaxel/Resveratrol-Coated Balloon Catheters. CardioVascular and Interventional Radiology, 2018, 41, 1599-1610.	0.9	19
42	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet, The, 2018, 392, 849-856.	6.3	263
43	Thrombus aspiration in non-ST-elevation myocardial infarction – 12-month clinical outcome of the randomised TATORT-NSTEMI trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 10-17.	0.4	13
44	The promise of leaving nothing behind — And how to manage its failure. Cardiovascular Revascularization Medicine, 2017, 18, 473-474.	0.3	0
45	A novel constrained, paclitaxel-coated angioplasty balloon catheter. EuroIntervention, 2017, 12, 2140-2147.	1.4	10
46	State of the art: balloon catheter technologies – drug-coated balloon. EuroIntervention, 2017, 13, 680-695.	1.4	39
47	Results From the International Drug Coated Balloon Registry for the Treatment of Bifurcations. Can a Bifurcation Be Treated Without Stents?. Journal of Interventional Cardiology, 2016, 29, 348-356.	0.5	17
48	Novel Sirolimus–Coated Balloon Catheter. Circulation: Cardiovascular Interventions, 2016, 9, e003543.	1.4	55
49	Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety study. International Journal of Cardiology, 2016, 225, 262-267.	0.8	29
50	Evaluation of occurring complications after flow diverter treatment of elastase-induced aneurysm in rabbits using micro-CT and MRI at 9.4ÂT. Neuroradiology, 2016, 58, 987-996.	1.1	13
51	A novel drugâ€coated scoring balloon for the treatment of coronary inâ€stent restenosis: Results from the multiâ€center randomized controlled <scp>PATENTâ€C</scp> first in human trial. Catheterization and Cardiovascular Interventions, 2016, 88, 51-59.	0.7	32
52	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. European Heart Journal, 2016, 37, 1096-1103.	1.0	73
53	Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. Clinical Research in Cardiology, 2016, 105, 613-621.	1.5	71
54	Drug-Coated Balloon Treatment as Default Strategy for DES-ISR. Journal of the American College of Cardiology, 2016, 67, 346-347.	1.2	6

#	Article	IF	CITATIONS
55	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 166-174.	1.1	39
56	Angioplasty of Femoral-Popliteal Arteries With Drug-CoatedÂBalloons. JACC: Cardiovascular Interventions, 2015, 8, 102-108.	1.1	230
57	Learning from mistakes: The case of drug-coated balloons. International Journal of Cardiology, 2015, 182, 224-226.	0.8	1
58	Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clinical Research in Cardiology, 2015, 104, 217-225.	1.5	143
59	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. EuroIntervention, 2015, 11, 926-934.	1.4	57
60	Drug-coated balloons in the treatment of small vessel disease: TableÂ1. Heart, 2014, 100, 274-275.	1.2	1
61	Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: Comparison with a drug eluting stent and a bare metal stent. Catheterization and Cardiovascular Interventions, 2014, 84, 323-331.	0.7	22
62	Stent Coverage and Neointimal Proliferation in Bare Metal Stents Postdilated With a Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2014, 7, 760-767.	1.4	26
63	Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. Clinical Research in Cardiology, 2014, 103, 21-27.	1.5	10
64	Effect of Aspiration Thrombectomy on Microvascular Obstruction in NSTEMI Patients. Journal of the American College of Cardiology, 2014, 64, 1117-1124.	1.2	75
65	Inhibition of neoâ€intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxelâ€coated scoring balloon catheter. Catheterization and Cardiovascular Interventions, 2014, 84, 1089-1098.	0.7	23
66	Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clinical Research in Cardiology, 2013, 102, 785-797.	1.5	157
67	Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6Âmonths. Clinical Research in Cardiology, 2013, 102, 469-472.	1.5	18
68	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?. EuroIntervention, 2013, 9, 620-628.	1.4	79
69	Management of recurrent in-stent restenosis: onion skin full metal jacket?. EuroIntervention, 2013, 9, 781-785.	1.4	10
70	Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel?. Circulation: Cardiovascular Interventions, 2012, 5, 392-400.	1.4	123
71	SeQuent Please World Wide Registry. Journal of the American College of Cardiology, 2012, 60, 1733-1738.	1.2	186
72	CD14++CD16+ Monocytes Independently Predict Cardiovascular Events. Journal of the American College of Cardiology, 2012, 60, 1512-1520.	1.2	449

#	Article	IF	CITATIONS
73	Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter. JACC: Cardiovascular Interventions, 2012, 5, 323-330.	1.1	197
74	Drug-Coated Balloons — The New Gold Standard for Treatment of Coronary In-Stent Restenosis?. Cardiovascular Revascularization Medicine, 2012, 13, 257-259.	0.3	4
75	Longâ€ŧerm effects on vascular healing of bare metal stents delivered via paclitaxelâ€coated balloons in the porcine model of restenosis. Catheterization and Cardiovascular Interventions, 2012, 80, 603-610.	0.7	23
76	Inhibition of neointimal proliferation after bare metal stent implantation with low-pressure drug delivery using a paclitaxel-coated balloon in porcine coronary arteries. Clinical Research in Cardiology, 2012, 101, 385-391.	1.5	17
77	Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clinical Research in Cardiology, 2012, 101, 469-476.	1.5	68
78	Drug Coated Balloons in Acute Coronary Syndromes - Opportunities and Limitations. Current Vascular Pharmacology, 2012, 10, 472-475.	0.8	4
79	Paclitaxel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study. EuroIntervention, 2012, 8, 450-455.	1.4	33
80	Dose Response to Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Overstretch and Stent Implantation Model. Investigative Radiology, 2011, 46, 255-263.	3.5	106
81	New technologies in percutaneous coronary interventions: drug-coated balloons. EuroIntervention, 2011, 7, K7-K7.	1.4	1
82	How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention, 2011, 7, K125-K128.	1.4	109
83	Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention, 2011, 7, K32-K42.	1.4	36
84	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clinical Research in Cardiology, 2010, 99, 165-174.	1.5	165
85	Best way to revascularize patients with main stem and three vessel lesions: patients should undergo PCII. Clinical Research in Cardiology, 2010, 99, 531-539.	1.5	9
86	Response to Letter Regarding Article, "Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis― Circulation, 2010, 121, .	1.6	1
87	Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis. Circulation, 2009, 119, 2986-2994.	1.6	451
88	Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clinical Research in Cardiology, 2009, 98, 325-330.	1.5	90
89	Drug-eluting balloon: Very short-term exposure and overlapping. Thrombosis and Haemostasis, 2009, 101, 201-206.	1.8	94
90	Drug-eluting balloon: very short-term exposure and overlapping. Thrombosis and Haemostasis, 2009, 101, 201-6.	1.8	25

#	Article	IF	CITATIONS
91	Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. Clinical Research in Cardiology, 2008, 97, 118-123.	1.5	11
92	Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clinical Research in Cardiology, 2008, 97, 773-781.	1.5	227
93	Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg. New England Journal of Medicine, 2008, 358, 689-699.	13.9	732
94	Prevention of restenosis: is angioplasty the answer?. Heart, 2007, 93, 539-541.	1.2	36
95	Reduction of Stenosis Due to Intimal Hyperplasia After Stent Supported Angioplasty of Peripheral Arteries by Local Administration of Paclitaxel in Swine. Investigative Radiology, 2007, 42, 579-585.	3.5	51
96	Neointima Inhibition: Comparison of Effectiveness of Non–Stent-based Local Drug Delivery and a Drug-eluting Stent in Porcine Coronary Arteries. Radiology, 2006, 240, 411-418.	3.6	111
97	Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter. New England Journal of Medicine, 2006, 355, 2113-2124.	13.9	675
98	Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis. Circulation, 2004, 110, 810-814.	1.6	394
99	Inhibition of Restenosis in Stented Porcine Coronary Arteries. Investigative Radiology, 2004, 39, 182-186.	3.5	45
100	Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. Journal of the American College of Cardiology, 2003, 42, 634-641.	1.2	228
101	Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. Journal of the American College of Cardiology, 2003, 42, 1415-1420.	1.2	137
102	Contrast media as carriers for local drug delivery Successful inhibition of neointimal proliferation in the porcine coronary stent model. European Heart Journal, 2003, 24, 1462-1467.	1.0	109
103	Acute Cardiac Tolerance of Current Contrast Media and the New Taxane Protaxel Using Iopromide as Carrier During Porcine Coronary Angiography and Stenting. Investigative Radiology, 2002, 37, 29-34.	3.5	18